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Identity 
Other names: STAT5 










The STAT5b gene is composed of 77229 base pairs 
and contains 19 exons. As exon 1 contains only the 5' 
UTR, there are 18 coding exons. The mRNA is 
composed of 5090 base pairs. 
Transcription 
There is one major transcript. 
 
The STAT5b gene. The STAT5b gene is composed of 19 exons that are transcribed as a 5090 nucleotide RNA transcript. The RNA is 
translated into the STAT5b protein containing 787 amino acids. 
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Schematic of the STAT5b protein. The STAT5b protein contains several conserved domains: the coiled-coil domain, the DNA binding 
domain, the SH2 domain, and the carboxy-terminal transactivation domain. While phosphorylation of Y699 is required for transcriptional 





STAT5b is composed of 787 amino acids (92 kD). 
Description 
STAT5b is a member of the signal transducer and 
activator of transcription (STAT) family. The STAT 
proteins contain several conserved domains: the coil d-
coil domain, the DNA binding domain, the SH2 
domain, and the carboxy-terminal transactivation 
domain. STATs remain latent in the cytoplasm until the
binding of a cytokine or growth factor to its receptor, 
resulting in recruitment of the STAT to the ligand 
receptor complex (Levy and Darnell, 2002; Herringto 
et al., 1999; Heim et al., 1995). The STAT protein is 
then phosphorylated by receptor tyrosine kinases or 
non-receptor tyrosine kinases, such as Janus kinases 
(JAKs) and Src family members. This phosphorylation 
results in SH2 domain mediated dimerization of STATs 
and their translocation to the nucleus. In the nucle s, 
STAT dimers bind to consensus DNA sequences and 
recruit additional transcription machinery to initiate 
specific gene regulation. To date, seven members of the 
STAT family have been identified (STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, and STAT6) 
(Silva, 2004; Calò et al., 2003; Moriggl et al., 1996; 
Liu et al., 1996; Liu et al., 1997). 
STAT5b is activated by a variety of stimuli, including 
interleukins, erythropoietin, growth hormone (GH), 
prolactin (Prl), and epidermal growth factor (EGF). 
Activation of STAT5b results in phosphorylation of 
tyrosine 699. Phosphorylation of this tyrosine is 
required for DNA binding and transcriptional activity. 
Mutation of Y699 of STAT5b inhibits stimulant-
induced tyrosine phosphorylation, DNA binding, and 
transcriptional activity (Gebert et al., 1997; Gouilleux 
et al., 1994; Kloth et al., 2003). Additional tyrosine 
phosphorylation sites (Y679, Y725, Y740, and Y743) 
and serine phosphorylation sites (S715, S731) have 
been shown to alter STAT5b transcriptional activity 
(Kloth et al., 2002; Weaver and Silva, 2006; Yamashit  
et al., 2001; Park et al., 2001; Decker and Kovarik, 
2000). 
While no classic nuclear localization signal (NLS) 
composed of a cluster of basic amino acids has been
reported for the STAT5b, the STAT5b dimer is actively 
translocated through the nuclear pore complex and 
accumulates in the nucleus upon phosphorylation (Xu 
and Massagué, 2004). 
STAT5b can be negatively regulated by phosphatase-
mediated dephosphorylation, ubiquitination-promoting 




STAT5b is localized in the cytoplasm and translocates 
to the nucleus upon phosphorylation of Y699. 
However, unphosphorylated STAT5b has also been 
reported to be found in the nucleus (Brown and Zeidler, 
2008; Iyer and Reich, 2008; Zeng et al., 2002). 
Function 
Transcription factor. STAT5b mediates the 
transcription of numerous genes in various cell 
signaling pathways involved in cellular proliferation, 
differentiation, and cell survival. The STATs bind 
TTC(N3)GAA gamma-interferon-activating sequence 
(GAS) sites in the promoters of target genes. 
Homology 
Shares homology with the other STAT family members 
(STAT1, 2, 3, 4, 5a, and 6). Additionally, STAT5a and 
STAT5b are 94% similar at the amino acid level, 
differing primarily at the C-terminus (Teglund et al., 




To date, there are 6 reported cases of humans having  
mutant STAT5b, and these cases result from five 
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different STAT5b mutations. The first STAT5b 
mutation in a human to be reported was the A630P 
STAT5b mutant. This single point mutation in the SH2 
domain causes missfolding of STAT5b. A nonsense 
mutation in the coiled-coil domain (R152X) results in 
the absence of detectable STAT5b protein. Insertion of 
a nucleotide in the DBD at position 1102 
(Q368fsX376) or 1191 (N398E) causes a frameshift 
mutation resulting in a non-functional truncated 
STAT5b. Likewise, a single nucleotide deletion in the 
linker domain at position 1680 (E561R) also results in 
a truncated STAT5b. In each of the 6 cases, STAT5b 
protein is not detectable, but STAT5a protein levels are 
unchanged. These reports are from homozygous 
patients while the parents are heterozygous for the 
STAT5b mutation and display a normal phenotype. The 
phenotype of each STAT5b mutant is similar: 
pronounced short stature, growth hormone insensitivity 
despite normal to high levels of GH in the serum, and
extremely low IGF-I and IGFBP-3 levels (Chia et al., 




STAT5b is implicated in prostate cancer (Koptyra et 
al., 2011; Clevenger, 2004), breast cancer (Bernaciak et 
al., 2009; Peck et al., 2011; Strauss et al., 2006; Sultan 
et al., 2005; Yamashita et al., 2003), lung cancer 
(Sánchez-Ceja et al., 2006), head and neck cancer 
(Koppikar et al., 2008), ovarian cancer (Chen et al., 
2004), hepatocellular carcinoma (Lee et al., 2006), 
cervical cancer (Lopez et al., 2011), and colorectal 
cancer (Du et al., 2011). 
Leukemias and lymphomas 
Note 
STAT5b is involved in the proliferation of chronic 
myeloid leukemia (CML) and acute myeloid leukemia 
(AML) cells (Baśkiewicz-Masiuk and Machalińkski, 
2004; Sternberg and Gilliland, 2004; Hoover et al.,
2001; de Groot et al., 1999). Additionally, STAT5b has 
been found to fuse with the retinoic acid receptor-alpha 
(RARalpha) gene in a subset of acute promyelocytic 
leukemias (APLL) (Arnould et al., 1999). Furthermore, 
STAT5b plays a role in the development of 
lymphoblastic lymphoma (Bessette et al., 2008; 
Nieborowska-Skorska et al., 2001). 
Laron type dwarfism II 
Note 
Laron type dwarfism II (LTD2) is mediated by defects 
in STAT5b (Nadeau et al., 2011; Freeth et al., 1998; 
Chia et al., 2006). 
Graft-versus-host disease 
Note 
Constitutively active STAT5b increases expansion of 
regulatory T cells (Treg), and these Tregs are more 
potent suppressors of graft-versus-host disease in vivo, 




Growth hormone reduces mucosal inflammation in 
colitis by activating STAT5b, such that STAT5b 
deficient mice demonstrated more severe colitis 
compared to wild-type mice (Han et al., 2006). 
Diabetes and metabolic disorder 
Note 
Upon leptin stimulation, the leptin receptor can mediate 
STAT5b tyrosine phosphorylation and transcriptional 
activity in the liver, gastrointestinal tract, and brain 
(Mütze et al., 2007; Ghilardi et al., 1996; Gong et al., 
2007). 
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